Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study

Atrash, Shebli; Thompson‐Leduc, Philippe; Tai, Ming-Hui; Kaila, Shuchita; Gray, Kathleen; Ghelerter, Isabelle; Lafeuille, Marie-Hélène; Jayabalan, David; Lefèbvre, Patrick; Rossi, Adriana

doi:10.1016/j.clml.2022.03.014

Cited by 2 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with studies in which outcomes are similar or even better when access to care is the same for Black patients with MM. 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 In the 2019 Surveillance Epidemiology, and End Results program data set, the 5-year relative survival of patients with MM was not different between Black (57.8%) and White (57.9%) patients. 4…”

Section: Discussionmentioning

confidence: 97%

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Shah,

Moshier,

Derkach

et al. 2024

Blood Advances

Self Cite

View full text Add to dashboard Cite

Multiple myeloma (MM) is twice as common in Black individuals compared to White, and diabetes mellitus (DM) disproportionately affects Black patients. While numerous studies have shown a correlation between DM and MM, this has not been studied in the context of race and in vivo mechanisms. We conducted a retrospective clinical study of 5383 patients with MM of which 15% had DM (12% White and 25% Black). Multivariable Cox models showed reduced overall survival (OS) for patients with DM (HR 1.27; 95% CI 1.11, 1.47; p<0.001). This appeared to be driven by a marked difference in OS between White patients with and without DM, but not Black patients. In contrast, obesity was associated with better OS in Black patients, but not White patients. To complement this analysis, we assessed MM growth in a genetically engineered immunocompromised non-obese diabetic (Rag1-/-/MKR) mouse model to evaluate the mechanisms linking DM and MM. MM.1S xenografts grew in more Rag1-/-/MKR mice and grew more rapidly in the Rag1-/-/MKR mice compared with controls. Western blot analysis found that MM1.S xenografts from Rag1-/-/MKR mice had higher phospho-S6 ribosomal protein(Ser235/236) levels indicating greater activation of the mammalian target of rapamycin pathway. Our study is the first to evaluate racial differences in DM prevalence and survival in MM as well as the effect of DM on tumor growth in mouse models. Our results suggest that DM may contribute to the higher incidence of MM in Black patients, and to improve survival in MM DM management cannot be ignored.

show abstract

Section: Discussionmentioning

confidence: 97%

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Shah,

Moshier,

Derkach

et al. 2024

Blood Advances

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, the universal applicability of risk categories based on cytogenetics has been challenged in acute myeloid leukaemia as black patients with AML harbouring NPM1 mutations do not show a favourable outcome [23]. In MM, two large British studies revealed a higher incidence of high-risk cytogenetic features in women than in men [5,6]. Interestingly, in the second study, the higher frequency of high-risk cytogenetics did not lead to impaired OS in women [8].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, there has been increasing evidence that the incidence of MM, the age at diagnosis, and the outcome vary among different ethnic groups with an increased incidence, a younger age at manifestation, and an overall favourable risk profile in black patients [4] although there clearly still are disparities in access to modern therapies [5,6]. In addition, within the widely studied Caucasian population with MM, evidence has recently emerged that sex may play a role with regard to the biology and outcome of MM.…”

Section: Introductionmentioning

confidence: 99%

Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort

Brioli¹,

Nägler²,

Yomade³

et al. 2022

Oncol Res Treat

View full text Add to dashboard Cite

Introduction: Multiple Myeloma (MM) is a plasma cell disease that affects more men than women. Although there is an obvious imbalance in incidence, knowledge on differences in biology and outcome between the sexes is surprisingly rare. Methods: We performed a unicentric retrospective analysis of patients with MM treated at a tertiary cancer center between 2003 and 2018. Results: We present sex-disaggregated analysis of the characteristics and outcome of MM in a cohort of 655 patients (median age at diagnosis 62 years; 363 men with a median age at diagnosis 62 years and 292 women with a median age at diagnosis 63 years, p=0.086). Most patients (n=561, 86%) received myeloma-specific treatment. Median overall survival was 76 months (95% CI 63 – 89) (72 months in men [95% CI 54 – 90] and 83 months in women [95% CI 66 – 100], p=ns). Apart from a higher incidence of moderate and severe anaemia in women (p<0.001) there were no statistically significant differences in the biology of the underlying MM. Similarly, in the group of patients who received high-dose therapy with autologous stem cell transplantation (ASCT, n=313), no statistically significant differences apart from more frequent anaemia in women were detected regarding the biology of the disease. However, there was a trend towards a higher plasma cell infiltration of the bone marrow and towards more frequent high-risk features in women. In contrast, relevant comorbidities were significantly more common in men (for example coronary heart disease in 13% of men vs. 2% of women, p<0.001). Toxicities after ASCT were not significantly different between the sexes with the exception of severe mucositis, which occurred in 22% of men vs. 40% of women (p=0.001). Conclusion: In conclusion, this first sex-disaggregated analysis of MM patients in Germany supports previous findings that survival is comparable amongst sexes, but women experience more toxicity of high-dose therapy. The higher incidence of clinically relevant anaemia in women warrants further investigation to exclude underlying treatable causes.

show abstract

Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study

Cited by 2 publications

References 28 publications

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort

Contact Info

Product

Resources

About